Improved plasma FFA/insulin homeostasis is independently associated with improved glucose tolerance after a 1-year lifestyle intervention in viscerally obese men

Diabetes Care

Volumn 36, Issue 10, 2013, Pages 3254-3261

  Borel, Anne Laure ^a   Boulet, Geneviève ^a   Nazare, Julie Anne ^a   Smith, Jessica ^a   Alméras, Natalie ^a   Tremblay, Angelo ^a,b   Bergeron, Jean ^c   Poirier, Paul ^a,b   Carpentier, André C ^d   Després, Jean Pierre ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d Centre Hospitalier Universitaire de Sherbrooke   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADULT; AGED; ARTICLE; BODY COMPOSITION; BODY FAT DISTRIBUTION; BODY SURFACE; BODY WEIGHT; CARDIORESPIRATORY FITNESS; COMPUTER ASSISTED TOMOGRAPHY; CROSS-SECTIONAL STUDY; DIET THERAPY; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSLIPIDEMIA; FATTY ACID BLOOD LEVEL; FEEDING BEHAVIOR; FEMALE; FITNESS; HEALTH PROGRAM; HEALTH STATUS; HOMEOSTASIS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OPEN STUDY; ORAL GLUCOSE TOLERANCE TEST; PHYSICAL ACTIVITY; REFERENCE VALUE; THERAPY EFFECT; WAIST CIRCUMFERENCE; YOUNG ADULT;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; BODY COMPOSITION; BODY WEIGHT; FATTY ACIDS, NONESTERIFIED; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; MALE; MIDDLE AGED; OBESITY, ABDOMINAL;

EID: 84891865317     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-2353     Document Type: Article

References (37)

1. Borel AL, Nazare JA, Smith J, et al. Visceral and not subcutaneous abdominal adiposity reduction drives the benefits of a 1-year lifestyle modification program. Obesity (Silver Spring) 2012;20:1223-1233
2. Smith JD, Borel AL, Nazare JA, et al. Visceral adipose tissue indicates the severity of cardiometabolic risk in patients with and without type 2 diabetes: results from the INSPIRE ME IAA study. J Clin Endocrinol Metab 2012;97:1517-1525
3. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444:881-887
4. Lebovitz HE, Banerji MA. Point: visceral adiposity is causally related to insulin resistance. Diabetes Care 2005;28:2322-2325
5. Roust LR, Jensen MD. Postprandial free fatty acid kinetics are abnormal in upper body obesity. Diabetes 1993;42:1567-1573
6. Nielsen S, Guo Z, Johnson CM, Hensrud DD, Jensen MD. Splanchnic lipolysis in human obesity. J Clin Invest 2004;113: 1582-1588
7. Boden G. Obesity and free fatty acids. Endocrinol Metab Clin North Am 2008; 37:635-646. viii-ix.
8. viii-ix 8. Mauriege P, Galitzky J, BerlanM, Lafontan M. Heterogeneous distribution of beta and alpha-2 adrenoceptor binding sites in human fat cells from various fat deposits: functional consequences. Eur J Clin Invest 1987;17:156-165
9. Mittelman SD, Van Citters GW, Kirkman EL, Bergman RN. Extreme insulin resistance of the central adipose depot in vivo. Diabetes 2002;51:755-761
10. Normand-Lauzière F, Frisch F, Labbé SM, et al. Increased postprandial nonesterified fatty acid appearance and oxidation in type 2 diabetes is not fully established in offspring of diabetic subjects. PLoS One 2010;5:e10956
11. Carpentier AC. Postprandial fatty acid metabolism in the development of lipotoxicity and type 2 diabetes. Diabetes Metab 2008;34:97-107
12. Giacca A, Xiao C, Oprescu AI, Carpentier AC, Lewis GF. Lipid-induced pancreatic b-cell dysfunction: focus on in vivo studies. Am J Physiol Endocrinol Metab 2011;300:E255-E262
13. Albu JB, Heilbronn LK, Kelley DE, et al.; Look AHEAD Adipose Research Group. Metabolic changes following a 1-year diet and exercise intervention in patients with type 2 diabetes. Diabetes 2010;59:627-633
14. Johnson NA, Sachinwalla T, Walton DW, et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009;50:1105-1112
15. Borel AL, Nazare JA, Smith J, et al. Improvement in insulin sensitivity following a 1-year lifestyle intervention program in viscerally obese men: contribution of abdominal adiposity. Metabolism 2012;61: 262-272
16. American College of Sports Medicine. ACSM's Guidelines for Exercise Testing and Prescription. 5th edition. Baltimore, Williams & Wilkins, 1995
17. Lohman TG, Roche A, Martorell R. Anthropometric Standardization Reference Manual, Champaign, Human Kinetics, 1988
18. Grundy SM, Cleeman JI, Daniels SR, et al.; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112:2735-2752
19. Ferland M, Després JP, Tremblay A, et al. Assessment of adipose tissue distribution by computed axial tomography in obese women: association with body density and anthropometric measurements. Br J Nutr 1989;61:139-148
20. Després JP, Ross R, Boka G, Alméras N, Lemieux I; ADAGIO-Lipids Investigators. Effect of rimonabant on the hightriglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arterioscler Thromb Vasc Biol 2009;29:416-423
21. Paré A, Dumont M, Lemieux I, et al. Is the relationship between adipose tissue and waist girth altered by weight loss in obese men? Obes Res 2001;9:526-534
22. Dole VP, Meinertz H. Microdetermination of long-chain fatty acids in plasma and tissues. J Biol Chem 1960;235:2595-2599
23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419
24. Abdul-Ghani MA,Molina-CarrionM, Jani R, Jenkinson C, Defronzo RA. Adipocytes in subjects with impaired fasting glucose and impaired glucose tolerance are resistant to the anti-lipolytic effect of insulin. Acta Diabetol 2008;45:147-150
25. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-1470
26. Couillard C, Bergeron N, Prud'homme D, et al. Postprandial triglyceride response in visceral obesity inmen. Diabetes 1998;47: 953-960
27. Couillard C, Bergeron N, Prud'homme D, et al. Gender difference in postprandial lipemia: importance of visceral adipose tissue accumulation. Arterioscler Thromb Vasc Biol 1999;19:2448-2455
28. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34: 1345-1353
29. FriedewaldWT, Levy RI, Fredrickson DS. Estimation of the concentration of lowdensity lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502
30. Riepponen P, Marniemi J, Rautaoja T. Immunoturbidimetric determination of apolipoproteins A-1 and B in serum. Scand J Clin Lab Invest 1987;47:739-744
31. Kelley DE, Kuller LH, McKolanis TM, Harper P, Mancino J, Kalhan S. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care 2004;27:33-40
32. Hallsworth K, Fattakhova G, Hollingsworth KG, et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut 2011;60:1278-1283
33. Miles JM, Wooldridge D, Grellner WJ, et al. Nocturnal and postprandial free fatty acid kinetics in normal and type 2 diabetic subjects: effects of insulin sensitization therapy. Diabetes 2003;52:675-681
34. Carpentier AC, Frisch F, Cyr D, et al. On the suppression of plasma nonesterified fatty acids by insulin during enhanced intravascular lipolysis in humans. Am J Physiol Endocrinol Metab 2005;289: E849-E856
35. Brassard P, Frisch F, Lavoie F, et al. Impaired plasma nonesterified fatty acid tolerance is an early defect in the natural history of type 2 diabetes. J Clin Endocrinol Metab 2008;93:837-844
36. Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab 2011;13:366-373
37. Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes 2006;55:1430-1435